Quercetin In The Treatment Of SARS-COV 2 — QUERCOV  

SARS (Severe Acute Respiratory Syndrome) Clinical Trial

Official title: Effectiveness of Quercetin In The Treatment of SARS-COV 2

Status Completed

Clinical Trial Summary

In 1937, Albert Szent-Gyorgyi received a Nobel Prize for discovering vitamin C and flavonoids, as well as for exploring their biochemical properties. Originally, he gave the flavonoids the name "vitamin P" because of their effectiveness in reducing the permeability of blood vessels. This name was abandoned when it was realized that these substances were not really vitamins.

Quercetin is extracted from a variety of plant sources, including the onion peel and the seeds and pods of Dimorphandra mollis, a legume tree native to South America.

Although we are far from knowing everything about quercetin, its antioxidant, anti-inflammatory, and antihistamine (antiallergic) properties have been observed in numerous in vitro and animal studies.

Clinical Trial Description

Properties

• Anti-oxidant, vascular protector

• Inhibition of platelet aggregation, vasorelaxant , arterial relaxant

• Anti-hypertensive , especially by certain derivatives (quercetin-3-glucuronic acid)

• Nephroprotective in rats, protects against the nephrotoxicity of gentamicin

• Anticancer , with immunostimulatory activity and inducer of apoptosis, with activity on the shock proteins HSP (heat shock proteins) hsp27 and hsp70

• Antitumor activity against prostate cancer and certain breast cancer cells

• Prevention of cardiac toxicity from doxorubicin, with resveratrol

• Protection against gastric inflammation associated with Helicobacter pylori infection by activity on MAPK, BCL-2, BAX.

• Increases the antitoxic activity of the liver

• Pancreatic lipase inhibitor, potential action in weight gain

• Anti-inflammatory

• Anti-allergic, inhibition of mast cell degranulation, with a preventive effect, reduction of inflammation linked to eosinophils (such as isoquercitrin regulates the Th1 / Th2 balance

• Antiviral (dose-dependent reduction of infectivity, decreases intracellular replication)

• Inhibition of rhinovirus replication

• Influenza prophylaxis by quercetin or its derivatives (quercetin-3-O-α-L-rhamnopyranoside), opposes the pro-oxidant effects induced by the influenza virus, antioxidant therapy could be used to prevent serious complications associated with influenza

• In vitro inhibition of the penetration of the Ebola virus by quercetin-3-O-glucoside

• Antiviral activity against Zika virus, hepatitis B virus, hepatitis C, Epstein-Barr virus EBV and antitumor against human gastric carcinoma ;

Related Conditions & MeSH terms

• SARS (Severe Acute Respiratory Syndrome)
• Severe Acute Respiratory Syndrome

• NCT number: NCT04853199
• Study type: Interventional
• Source: Hôpital Universitaire Sahloul
• Status: Completed
• Phase: Early Phase 1
• Start date: June 1, 2021
• Completion date: August 30, 2021